Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G R Mirick

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 18, 1999
Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemiaG L DeNardo, S J DeNardo, S Shen, et al.
International Journal of Oncology|January 17, 2009
Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemiaG L DeNardo, G R Mirick, S Hok, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 6, 2001
Metabolite production in patients with lymphoma after radiometal-labeled antibody administrationG L DeNardo, S J DeNardo, D L Kukis, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2000
Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenograftsR T O'Donnell, S J DeNardo, L A Miers, et al.
The Prostate|October 6, 1998
L6 monoclonal antibody binds prostate cancerR T O'Donnell, S J DeNardo, X B Shi, et al.
Nuclear Medicine Communications|July 1, 1993
Body and blood clearance and marrow radiation dose of 131I-Lym-1 in patients with B-cell malignanciesG L DeNardo, M A Mahe, S J DeNardo, et al.
Cancer Research|February 15, 1995
Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugatesD L Kukis, G L DeNardo, S J DeNardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphomaR T O'Donnell, G L DeNardo, D L Kukis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 5, 2000
A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphomaR T O'Donnell, G L DeNardo, D L Kukis, et al.
Cancer|February 1, 1994
The biologic window for chimeric L6 radioimmunotherapyS J DeNardo, G R Mirick, L A Kroger, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 18, 1999
Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemiaG L DeNardo, S J DeNardo, S Shen, et al.
International Journal of Oncology|January 17, 2009
Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemiaG L DeNardo, G R Mirick, S Hok, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 6, 2001
Metabolite production in patients with lymphoma after radiometal-labeled antibody administrationG L DeNardo, S J DeNardo, D L Kukis, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2000
Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenograftsR T O'Donnell, S J DeNardo, L A Miers, et al.
The Prostate|October 6, 1998
L6 monoclonal antibody binds prostate cancerR T O'Donnell, S J DeNardo, X B Shi, et al.
Nuclear Medicine Communications|July 1, 1993
Body and blood clearance and marrow radiation dose of 131I-Lym-1 in patients with B-cell malignanciesG L DeNardo, M A Mahe, S J DeNardo, et al.
Cancer Research|February 15, 1995
Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugatesD L Kukis, G L DeNardo, S J DeNardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphomaR T O'Donnell, G L DeNardo, D L Kukis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 5, 2000
A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphomaR T O'Donnell, G L DeNardo, D L Kukis, et al.
Cancer|February 1, 1994
The biologic window for chimeric L6 radioimmunotherapyS J DeNardo, G R Mirick, L A Kroger, et al.
Pageof 3